nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP1A2—chronic obstructive pulmonary disease	0.323	0.634	CbGaD
Vemurafenib—ALB—chronic obstructive pulmonary disease	0.187	0.366	CbGaD
Vemurafenib—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0392	0.133	CbGbCtD
Vemurafenib—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.038	0.129	CbGbCtD
Vemurafenib—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.038	0.129	CbGbCtD
Vemurafenib—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0339	0.115	CbGbCtD
Vemurafenib—ALB—Prednisone—chronic obstructive pulmonary disease	0.0324	0.11	CbGbCtD
Vemurafenib—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0319	0.108	CbGbCtD
Vemurafenib—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0215	0.0731	CbGbCtD
Vemurafenib—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0206	0.0697	CbGbCtD
Vemurafenib—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0183	0.0622	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0107	0.0365	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0101	0.0344	CbGbCtD
Vemurafenib—Etoricoxib—CYP1A2—chronic obstructive pulmonary disease	0.00241	1	CrCbGaD
Vemurafenib—Vasculitis—Montelukast—chronic obstructive pulmonary disease	0.000976	0.00898	CcSEcCtD
Vemurafenib—Connective tissue disorder—Roflumilast—chronic obstructive pulmonary disease	0.000945	0.0087	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Salbutamol—chronic obstructive pulmonary disease	0.000929	0.00855	CcSEcCtD
Vemurafenib—Arthritis—Tiotropium—chronic obstructive pulmonary disease	0.0009	0.00828	CcSEcCtD
Vemurafenib—Cardiac disorder—Roflumilast—chronic obstructive pulmonary disease	0.000893	0.00821	CcSEcCtD
Vemurafenib—Neoplasm—Arformoterol—chronic obstructive pulmonary disease	0.000879	0.00809	CcSEcCtD
Vemurafenib—Neoplasm—Formoterol—chronic obstructive pulmonary disease	0.000879	0.00809	CcSEcCtD
Vemurafenib—Pain in extremity—Tiotropium—chronic obstructive pulmonary disease	0.000874	0.00805	CcSEcCtD
Vemurafenib—Mediastinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.000867	0.00798	CcSEcCtD
Vemurafenib—Malnutrition—Roflumilast—chronic obstructive pulmonary disease	0.000837	0.00771	CcSEcCtD
Vemurafenib—Dysgeusia—Roflumilast—chronic obstructive pulmonary disease	0.00082	0.00755	CcSEcCtD
Vemurafenib—Back pain—Roflumilast—chronic obstructive pulmonary disease	0.00081	0.00745	CcSEcCtD
Vemurafenib—Dry skin—Tiotropium—chronic obstructive pulmonary disease	0.000802	0.00738	CcSEcCtD
Vemurafenib—Atrial fibrillation—Arformoterol—chronic obstructive pulmonary disease	0.000745	0.00685	CcSEcCtD
Vemurafenib—Atrial fibrillation—Formoterol—chronic obstructive pulmonary disease	0.000745	0.00685	CcSEcCtD
Vemurafenib—Arthritis—Formoterol—chronic obstructive pulmonary disease	0.000726	0.00668	CcSEcCtD
Vemurafenib—Arthritis—Arformoterol—chronic obstructive pulmonary disease	0.000726	0.00668	CcSEcCtD
Vemurafenib—Myalgia—Roflumilast—chronic obstructive pulmonary disease	0.000713	0.00656	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.000708	0.00651	CcSEcCtD
Vemurafenib—Atrial fibrillation—Salbutamol—chronic obstructive pulmonary disease	0.000703	0.00647	CcSEcCtD
Vemurafenib—Infection—Roflumilast—chronic obstructive pulmonary disease	0.000679	0.00625	CcSEcCtD
Vemurafenib—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00067	0.00617	CcSEcCtD
Vemurafenib—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000664	0.00611	CcSEcCtD
Vemurafenib—Dry skin—Arformoterol—chronic obstructive pulmonary disease	0.000647	0.00595	CcSEcCtD
Vemurafenib—Dry skin—Formoterol—chronic obstructive pulmonary disease	0.000647	0.00595	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000623	0.00573	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Montelukast—chronic obstructive pulmonary disease	0.000622	0.00573	CcSEcCtD
Vemurafenib—Oedema peripheral—Tiotropium—chronic obstructive pulmonary disease	0.000596	0.00548	CcSEcCtD
Vemurafenib—Connective tissue disorder—Tiotropium—chronic obstructive pulmonary disease	0.000594	0.00547	CcSEcCtD
Vemurafenib—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.000594	0.00547	CcSEcCtD
Vemurafenib—Eosinophilia—Montelukast—chronic obstructive pulmonary disease	0.000592	0.00544	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00059	0.00543	CcSEcCtD
Vemurafenib—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.000589	0.00542	CcSEcCtD
Vemurafenib—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000584	0.00538	CcSEcCtD
Vemurafenib—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.000567	0.00522	CcSEcCtD
Vemurafenib—Eye disorder—Tiotropium—chronic obstructive pulmonary disease	0.000565	0.0052	CcSEcCtD
Vemurafenib—Angiopathy—Tiotropium—chronic obstructive pulmonary disease	0.000549	0.00505	CcSEcCtD
Vemurafenib—Mediastinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000545	0.00502	CcSEcCtD
Vemurafenib—Vasculitis—Prednisolone—chronic obstructive pulmonary disease	0.000539	0.00496	CcSEcCtD
Vemurafenib—Infestation NOS—Montelukast—chronic obstructive pulmonary disease	0.000533	0.0049	CcSEcCtD
Vemurafenib—Infestation—Montelukast—chronic obstructive pulmonary disease	0.000533	0.0049	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.000528	0.00486	CcSEcCtD
Vemurafenib—Malnutrition—Tiotropium—chronic obstructive pulmonary disease	0.000527	0.00485	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Montelukast—chronic obstructive pulmonary disease	0.000522	0.0048	CcSEcCtD
Vemurafenib—Back pain—Tiotropium—chronic obstructive pulmonary disease	0.000509	0.00469	CcSEcCtD
Vemurafenib—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000504	0.00463	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Salbutamol—chronic obstructive pulmonary disease	0.000503	0.00463	CcSEcCtD
Vemurafenib—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00049	0.00451	CcSEcCtD
Vemurafenib—Oedema peripheral—Arformoterol—chronic obstructive pulmonary disease	0.000481	0.00443	CcSEcCtD
Vemurafenib—Oedema peripheral—Formoterol—chronic obstructive pulmonary disease	0.000481	0.00443	CcSEcCtD
Vemurafenib—Connective tissue disorder—Arformoterol—chronic obstructive pulmonary disease	0.00048	0.00441	CcSEcCtD
Vemurafenib—Connective tissue disorder—Formoterol—chronic obstructive pulmonary disease	0.00048	0.00441	CcSEcCtD
Vemurafenib—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.00047	0.00432	CcSEcCtD
Vemurafenib—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000468	0.0043	CcSEcCtD
Vemurafenib—Cough—Tiotropium—chronic obstructive pulmonary disease	0.00046	0.00423	CcSEcCtD
Vemurafenib—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000456	0.00419	CcSEcCtD
Vemurafenib—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000453	0.00417	CcSEcCtD
Vemurafenib—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000453	0.00417	CcSEcCtD
Vemurafenib—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000453	0.00417	CcSEcCtD
Vemurafenib—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000453	0.00417	CcSEcCtD
Vemurafenib—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000452	0.00416	CcSEcCtD
Vemurafenib—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000452	0.00416	CcSEcCtD
Vemurafenib—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000448	0.00413	CcSEcCtD
Vemurafenib—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000448	0.00413	CcSEcCtD
Vemurafenib—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000447	0.00411	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000445	0.0041	CcSEcCtD
Vemurafenib—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000444	0.00408	CcSEcCtD
Vemurafenib—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00044	0.00405	CcSEcCtD
Vemurafenib—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00044	0.00405	CcSEcCtD
Vemurafenib—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000435	0.004	CcSEcCtD
Vemurafenib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000431	0.00397	CcSEcCtD
Vemurafenib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000431	0.00397	CcSEcCtD
Vemurafenib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000431	0.00396	CcSEcCtD
Vemurafenib—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000428	0.00394	CcSEcCtD
Vemurafenib—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000428	0.00394	CcSEcCtD
Vemurafenib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000427	0.00393	CcSEcCtD
Vemurafenib—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000426	0.00392	CcSEcCtD
Vemurafenib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000425	0.00391	CcSEcCtD
Vemurafenib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000425	0.00391	CcSEcCtD
Vemurafenib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000421	0.00388	CcSEcCtD
Vemurafenib—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000418	0.00385	CcSEcCtD
Vemurafenib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000417	0.00384	CcSEcCtD
Vemurafenib—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000416	0.00383	CcSEcCtD
Vemurafenib—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000416	0.00383	CcSEcCtD
Vemurafenib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000415	0.00382	CcSEcCtD
Vemurafenib—Chills—Salbutamol—chronic obstructive pulmonary disease	0.000414	0.00381	CcSEcCtD
Vemurafenib—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000411	0.00378	CcSEcCtD
Vemurafenib—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000411	0.00378	CcSEcCtD
Vemurafenib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000406	0.00374	CcSEcCtD
Vemurafenib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000401	0.00369	CcSEcCtD
Vemurafenib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000396	0.00365	CcSEcCtD
Vemurafenib—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000393	0.00362	CcSEcCtD
Vemurafenib—Vasculitis—Prednisone—chronic obstructive pulmonary disease	0.000392	0.00361	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000392	0.0036	CcSEcCtD
Vemurafenib—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000388	0.00357	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000371	0.00341	CcSEcCtD
Vemurafenib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000371	0.00341	CcSEcCtD
Vemurafenib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000371	0.00341	CcSEcCtD
Vemurafenib—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000368	0.00338	CcSEcCtD
Vemurafenib—Cough—Montelukast—chronic obstructive pulmonary disease	0.000363	0.00334	CcSEcCtD
Vemurafenib—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000362	0.00333	CcSEcCtD
Vemurafenib—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000362	0.00333	CcSEcCtD
Vemurafenib—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000362	0.00333	CcSEcCtD
Vemurafenib—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000362	0.00333	CcSEcCtD
Vemurafenib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00036	0.00332	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000359	0.00331	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000359	0.00331	CcSEcCtD
Vemurafenib—RAF1—respiratory system—chronic obstructive pulmonary disease	0.000358	0.128	CbGeAlD
Vemurafenib—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000354	0.00326	CcSEcCtD
Vemurafenib—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000354	0.00326	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000352	0.00324	CcSEcCtD
Vemurafenib—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00035	0.00322	CcSEcCtD
Vemurafenib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00035	0.00322	CcSEcCtD
Vemurafenib—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000347	0.00319	CcSEcCtD
Vemurafenib—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000347	0.00319	CcSEcCtD
Vemurafenib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00317	CcSEcCtD
Vemurafenib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00317	CcSEcCtD
Vemurafenib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.00314	CcSEcCtD
Vemurafenib—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.00314	CcSEcCtD
Vemurafenib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00313	CcSEcCtD
Vemurafenib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00313	CcSEcCtD
Vemurafenib—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00034	0.00313	CcSEcCtD
Vemurafenib—Infection—Montelukast—chronic obstructive pulmonary disease	0.000338	0.00311	CcSEcCtD
Vemurafenib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000337	0.0031	CcSEcCtD
Vemurafenib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000337	0.0031	CcSEcCtD
Vemurafenib—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000336	0.00309	CcSEcCtD
Vemurafenib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000333	0.00307	CcSEcCtD
Vemurafenib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00033	0.00304	CcSEcCtD
Vemurafenib—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00301	CcSEcCtD
Vemurafenib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000325	0.00299	CcSEcCtD
Vemurafenib—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000324	0.00298	CcSEcCtD
Vemurafenib—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000324	0.00298	CcSEcCtD
Vemurafenib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000322	0.00297	CcSEcCtD
Vemurafenib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00296	CcSEcCtD
Vemurafenib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000318	0.00293	CcSEcCtD
Vemurafenib—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000317	0.00291	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000316	0.00291	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000316	0.00291	CcSEcCtD
Vemurafenib—RAF1—connective tissue—chronic obstructive pulmonary disease	0.000315	0.113	CbGeAlD
Vemurafenib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000312	0.00287	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.00031	0.00285	CcSEcCtD
Vemurafenib—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000306	0.00282	CcSEcCtD
Vemurafenib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000304	0.0028	CcSEcCtD
Vemurafenib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000301	0.00277	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.00276	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000299	0.00276	CcSEcCtD
Vemurafenib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.00275	CcSEcCtD
Vemurafenib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000299	0.00275	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000298	0.00275	CcSEcCtD
Vemurafenib—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000297	0.00273	CcSEcCtD
Vemurafenib—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000297	0.00273	CcSEcCtD
Vemurafenib—RAF1—bronchus—chronic obstructive pulmonary disease	0.000294	0.105	CbGeAlD
Vemurafenib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000293	0.0027	CcSEcCtD
Vemurafenib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000293	0.0027	CcSEcCtD
Vemurafenib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00029	0.00267	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000289	0.00266	CcSEcCtD
Vemurafenib—RAF1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000288	0.103	CbGeAlD
Vemurafenib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000287	0.00264	CcSEcCtD
Vemurafenib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000287	0.00264	CcSEcCtD
Vemurafenib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000286	0.00263	CcSEcCtD
Vemurafenib—BRAF—lung—chronic obstructive pulmonary disease	0.000285	0.102	CbGeAlD
Vemurafenib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.00262	CcSEcCtD
Vemurafenib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000284	0.00262	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.0026	CcSEcCtD
Vemurafenib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.0026	CcSEcCtD
Vemurafenib—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00028	0.00258	CcSEcCtD
Vemurafenib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000274	0.00252	CcSEcCtD
Vemurafenib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000274	0.00252	CcSEcCtD
Vemurafenib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000273	0.00251	CcSEcCtD
Vemurafenib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000271	0.00249	CcSEcCtD
Vemurafenib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000271	0.00249	CcSEcCtD
Vemurafenib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000271	0.00249	CcSEcCtD
Vemurafenib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000269	0.00248	CcSEcCtD
Vemurafenib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000269	0.00247	CcSEcCtD
Vemurafenib—RAF1—trachea—chronic obstructive pulmonary disease	0.000264	0.0945	CbGeAlD
Vemurafenib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000259	0.00238	CcSEcCtD
Vemurafenib—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000256	0.00235	CcSEcCtD
Vemurafenib—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000256	0.00235	CcSEcCtD
Vemurafenib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000255	0.00235	CcSEcCtD
Vemurafenib—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000255	0.00234	CcSEcCtD
Vemurafenib—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.00025	0.0023	CcSEcCtD
Vemurafenib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000249	0.00229	CcSEcCtD
Vemurafenib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.00229	CcSEcCtD
Vemurafenib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000245	0.00226	CcSEcCtD
Vemurafenib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000245	0.00226	CcSEcCtD
Vemurafenib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00224	CcSEcCtD
Vemurafenib—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.00222	CcSEcCtD
Vemurafenib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.00024	0.00221	CcSEcCtD
Vemurafenib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000237	0.00218	CcSEcCtD
Vemurafenib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.00218	CcSEcCtD
Vemurafenib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00216	CcSEcCtD
Vemurafenib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000232	0.00214	CcSEcCtD
Vemurafenib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.00213	CcSEcCtD
Vemurafenib—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00023	0.00212	CcSEcCtD
Vemurafenib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000229	0.00211	CcSEcCtD
Vemurafenib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000229	0.00211	CcSEcCtD
Vemurafenib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000225	0.00207	CcSEcCtD
Vemurafenib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00206	CcSEcCtD
Vemurafenib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.00203	CcSEcCtD
Vemurafenib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000221	0.00203	CcSEcCtD
Vemurafenib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000219	0.00201	CcSEcCtD
Vemurafenib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.00201	CcSEcCtD
Vemurafenib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00201	CcSEcCtD
Vemurafenib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00201	CcSEcCtD
Vemurafenib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000217	0.002	CcSEcCtD
Vemurafenib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000217	0.002	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000217	0.002	CcSEcCtD
Vemurafenib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00199	CcSEcCtD
Vemurafenib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000216	0.00199	CcSEcCtD
Vemurafenib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000214	0.00197	CcSEcCtD
Vemurafenib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000214	0.00197	CcSEcCtD
Vemurafenib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000213	0.00196	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.00021	0.00193	CcSEcCtD
Vemurafenib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00192	CcSEcCtD
Vemurafenib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.0019	CcSEcCtD
Vemurafenib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.0019	CcSEcCtD
Vemurafenib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000206	0.0019	CcSEcCtD
Vemurafenib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000206	0.0019	CcSEcCtD
Vemurafenib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000205	0.00189	CcSEcCtD
Vemurafenib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00186	CcSEcCtD
Vemurafenib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00179	CcSEcCtD
Vemurafenib—RAF1—lung—chronic obstructive pulmonary disease	0.00019	0.0679	CbGeAlD
Vemurafenib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000189	0.00174	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000188	0.00173	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.00018	0.00165	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000174	0.0016	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.00017	0.00156	CcSEcCtD
Vemurafenib—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000167	0.00154	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000167	0.00154	CcSEcCtD
Vemurafenib—ABCC1—bronchus—chronic obstructive pulmonary disease	0.000147	0.0526	CbGeAlD
Vemurafenib—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000142	0.0509	CbGeAlD
Vemurafenib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000142	0.00131	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000142	0.00131	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000141	0.0013	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000138	0.00127	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000137	0.00126	CcSEcCtD
Vemurafenib—Infection—Prednisone—chronic obstructive pulmonary disease	0.000136	0.00125	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000134	0.00123	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000133	0.00122	CcSEcCtD
Vemurafenib—ABCC1—trachea—chronic obstructive pulmonary disease	0.000132	0.0472	CbGeAlD
Vemurafenib—ORM1—lung—chronic obstructive pulmonary disease	0.000131	0.0469	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000124	0.00114	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.00114	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00109	CcSEcCtD
Vemurafenib—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00109	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00109	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000118	0.00108	CcSEcCtD
Vemurafenib—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000118	0.00108	CcSEcCtD
Vemurafenib—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00107	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.00103	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000993	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000925	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—chronic obstructive pulmonary disease	9.79e-05	0.000901	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—chronic obstructive pulmonary disease	9.66e-05	0.000889	CcSEcCtD
Vemurafenib—ABCC1—lung—chronic obstructive pulmonary disease	9.49e-05	0.0339	CbGeAlD
Vemurafenib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	9.34e-05	0.000859	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—chronic obstructive pulmonary disease	9.03e-05	0.000831	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—chronic obstructive pulmonary disease	8.68e-05	0.000799	CcSEcCtD
Vemurafenib—Rash—Prednisone—chronic obstructive pulmonary disease	8.61e-05	0.000792	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.000791	CcSEcCtD
Vemurafenib—Headache—Prednisone—chronic obstructive pulmonary disease	8.55e-05	0.000787	CcSEcCtD
Vemurafenib—Nausea—Prednisone—chronic obstructive pulmonary disease	8.11e-05	0.000746	CcSEcCtD
Vemurafenib—ABCG2—lung—chronic obstructive pulmonary disease	7.86e-05	0.0281	CbGeAlD
Vemurafenib—CYP1A2—lung—chronic obstructive pulmonary disease	7.56e-05	0.027	CbGeAlD
Vemurafenib—RAF1—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	4.15e-05	0.00051	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.11e-05	0.000506	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.09e-05	0.000502	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	4.07e-05	0.0005	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.06e-05	0.000499	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	4.05e-05	0.000498	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.03e-05	0.000495	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	4e-05	0.000492	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	3.99e-05	0.00049	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.94e-05	0.000485	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KL—chronic obstructive pulmonary disease	3.93e-05	0.000483	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	3.92e-05	0.000481	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD8A—chronic obstructive pulmonary disease	3.91e-05	0.000481	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	3.91e-05	0.00048	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.89e-05	0.000478	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.87e-05	0.000476	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	3.86e-05	0.000474	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL1B—chronic obstructive pulmonary disease	3.85e-05	0.000474	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—LEP—chronic obstructive pulmonary disease	3.84e-05	0.000472	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.82e-05	0.00047	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.82e-05	0.00047	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	3.8e-05	0.000467	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	3.8e-05	0.000467	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	3.79e-05	0.000466	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	3.75e-05	0.000461	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	3.74e-05	0.00046	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—chronic obstructive pulmonary disease	3.71e-05	0.000456	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.71e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	3.68e-05	0.000452	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.68e-05	0.000452	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ERBB3—chronic obstructive pulmonary disease	3.64e-05	0.000447	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	3.63e-05	0.000446	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	3.62e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.62e-05	0.000445	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	3.51e-05	0.000432	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.51e-05	0.000431	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	3.5e-05	0.00043	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	3.48e-05	0.000428	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.47e-05	0.000427	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CRP—chronic obstructive pulmonary disease	3.46e-05	0.000426	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—chronic obstructive pulmonary disease	3.46e-05	0.000426	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.43e-05	0.000422	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.38e-05	0.000416	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.35e-05	0.000412	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TLR4—chronic obstructive pulmonary disease	3.32e-05	0.000408	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—chronic obstructive pulmonary disease	3.26e-05	0.0004	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	3.26e-05	0.0004	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	3.26e-05	0.0004	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	3.25e-05	0.0004	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—chronic obstructive pulmonary disease	3.23e-05	0.000397	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	3.23e-05	0.000397	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—chronic obstructive pulmonary disease	3.21e-05	0.000394	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	3.2e-05	0.000393	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	3.19e-05	0.000392	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.18e-05	0.00039	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.15e-05	0.000388	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TLR2—chronic obstructive pulmonary disease	3.13e-05	0.000385	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.12e-05	0.000383	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.11e-05	0.000382	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	3.09e-05	0.000379	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	3.07e-05	0.000377	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.99e-05	0.000367	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.97e-05	0.000366	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.96e-05	0.000364	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.96e-05	0.000363	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.95e-05	0.000363	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ALB—chronic obstructive pulmonary disease	2.95e-05	0.000363	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.95e-05	0.000362	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB3—chronic obstructive pulmonary disease	2.95e-05	0.000362	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KL—chronic obstructive pulmonary disease	2.94e-05	0.000362	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	2.93e-05	0.00036	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.93e-05	0.00036	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HDAC2—chronic obstructive pulmonary disease	2.92e-05	0.000359	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—chronic obstructive pulmonary disease	2.9e-05	0.000357	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HDAC2—chronic obstructive pulmonary disease	2.9e-05	0.000356	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.89e-05	0.000355	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	2.89e-05	0.000355	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	2.89e-05	0.000355	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GC—chronic obstructive pulmonary disease	2.87e-05	0.000353	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GCLC—chronic obstructive pulmonary disease	2.85e-05	0.000351	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.82e-05	0.000347	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.8e-05	0.000344	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	2.79e-05	0.000343	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.75e-05	0.000338	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KL—chronic obstructive pulmonary disease	2.72e-05	0.000334	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KL—chronic obstructive pulmonary disease	2.69e-05	0.000331	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.67e-05	0.000328	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.66e-05	0.000327	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.66e-05	0.000327	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—chronic obstructive pulmonary disease	2.61e-05	0.000321	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.61e-05	0.00032	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.55e-05	0.000314	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.54e-05	0.000312	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.54e-05	0.000312	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.53e-05	0.000311	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GCLC—chronic obstructive pulmonary disease	2.51e-05	0.000309	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS2—chronic obstructive pulmonary disease	2.46e-05	0.000302	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.44e-05	0.000299	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.4e-05	0.000296	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.4e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—chronic obstructive pulmonary disease	2.37e-05	0.000292	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.37e-05	0.000291	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.32e-05	0.000286	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—chronic obstructive pulmonary disease	2.31e-05	0.000284	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CTGF—chronic obstructive pulmonary disease	2.29e-05	0.000282	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.29e-05	0.000281	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.27e-05	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—chronic obstructive pulmonary disease	2.26e-05	0.000277	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.23e-05	0.000274	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.22e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—chronic obstructive pulmonary disease	2.22e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB3—chronic obstructive pulmonary disease	2.21e-05	0.000271	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.2e-05	0.000271	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.13e-05	0.000261	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	2.12e-05	0.000261	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.11e-05	0.00026	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	2.09e-05	0.000257	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	2.07e-05	0.000255	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SERPINE1—chronic obstructive pulmonary disease	2.07e-05	0.000254	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.06e-05	0.000254	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.06e-05	0.000254	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	2.06e-05	0.000253	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.05e-05	0.000252	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB3—chronic obstructive pulmonary disease	2.04e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—chronic obstructive pulmonary disease	2.03e-05	0.00025	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB3—chronic obstructive pulmonary disease	2.02e-05	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CRP—chronic obstructive pulmonary disease	2.02e-05	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—chronic obstructive pulmonary disease	2.01e-05	0.000247	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.01e-05	0.000247	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2e-05	0.000246	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.99e-05	0.000244	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS3—chronic obstructive pulmonary disease	1.97e-05	0.000243	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.97e-05	0.000243	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.95e-05	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TLR4—chronic obstructive pulmonary disease	1.93e-05	0.000238	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.9e-05	0.000234	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	1.9e-05	0.000234	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.89e-05	0.000232	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.87e-05	0.000229	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.87e-05	0.000229	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—chronic obstructive pulmonary disease	1.86e-05	0.000229	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.85e-05	0.000227	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.84e-05	0.000226	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—chronic obstructive pulmonary disease	1.78e-05	0.000218	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.76e-05	0.000217	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.76e-05	0.000216	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.74e-05	0.000214	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.74e-05	0.000214	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—chronic obstructive pulmonary disease	1.7e-05	0.000209	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—chronic obstructive pulmonary disease	1.68e-05	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—chronic obstructive pulmonary disease	1.65e-05	0.000202	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.62e-05	0.000199	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.59e-05	0.000196	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	1.59e-05	0.000196	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	1.58e-05	0.000194	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.57e-05	0.000193	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.57e-05	0.000193	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	1.55e-05	0.000191	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.55e-05	0.00019	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—chronic obstructive pulmonary disease	1.54e-05	0.000189	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.53e-05	0.000189	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	1.52e-05	0.000187	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.49e-05	0.000183	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.45e-05	0.000178	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.44e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.44e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—chronic obstructive pulmonary disease	1.43e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.43e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.43e-05	0.000175	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SERPINE1—chronic obstructive pulmonary disease	1.42e-05	0.000174	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000174	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.38e-05	0.00017	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.37e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS3—chronic obstructive pulmonary disease	1.37e-05	0.000168	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS3—chronic obstructive pulmonary disease	1.35e-05	0.000166	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—chronic obstructive pulmonary disease	1.31e-05	0.00016	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.00016	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.29e-05	0.000159	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—chronic obstructive pulmonary disease	1.28e-05	0.000157	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.28e-05	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.28e-05	0.000157	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—chronic obstructive pulmonary disease	1.27e-05	0.000156	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—chronic obstructive pulmonary disease	1.26e-05	0.000155	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.23e-05	0.000151	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—chronic obstructive pulmonary disease	1.19e-05	0.000146	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.17e-05	0.000144	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.13e-05	0.000139	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.11e-05	0.000136	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.1e-05	0.000135	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.09e-05	0.000134	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.09e-05	0.000134	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.08e-05	0.000133	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	0.000132	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000132	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.05e-05	0.000129	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—chronic obstructive pulmonary disease	1.04e-05	0.000128	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.01e-05	0.000124	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1e-05	0.000123	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1e-05	0.000123	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.99e-06	0.000123	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NOS3—chronic obstructive pulmonary disease	9.98e-06	0.000123	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	9.96e-06	0.000122	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.89e-06	0.000122	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—chronic obstructive pulmonary disease	9.84e-06	0.000121	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—chronic obstructive pulmonary disease	9.59e-06	0.000118	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.57e-06	0.000118	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.47e-06	0.000116	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	9.14e-06	0.000112	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—chronic obstructive pulmonary disease	9.03e-06	0.000111	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.97e-06	0.00011	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	8.96e-06	0.00011	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—chronic obstructive pulmonary disease	8.95e-06	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—chronic obstructive pulmonary disease	8.86e-06	0.000109	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.85e-06	0.000109	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—chronic obstructive pulmonary disease	8.78e-06	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.48e-06	0.000104	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.47e-06	0.000104	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.37e-06	0.000103	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	8.27e-06	0.000102	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.25e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.07e-06	9.92e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.82e-06	9.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.67e-06	9.43e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	7.64e-06	9.39e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.6e-06	9.35e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—chronic obstructive pulmonary disease	7.53e-06	9.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.5e-06	9.22e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—chronic obstructive pulmonary disease	7.37e-06	9.06e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.03e-06	8.65e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.99e-06	8.59e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.89e-06	8.47e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.89e-06	8.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—chronic obstructive pulmonary disease	6.81e-06	8.37e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—chronic obstructive pulmonary disease	6.75e-06	8.29e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.62e-06	8.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.32e-06	7.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.2e-06	7.62e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	6.16e-06	7.57e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.87e-06	7.21e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.79e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.39e-06	6.63e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	5.31e-06	6.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.21e-06	6.4e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.11e-06	6.28e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.08e-06	6.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.77e-06	5.86e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.5e-06	5.53e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.31e-06	5.29e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.47e-06	4.27e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.32e-06	4.09e-05	CbGpPWpGaD
